Finland· FI-REL-REL61906
Pomalidomide STADA
A pomalidomide product containing pomalidomide, registered in Finland by STADA Arzneimittel AG. The same ATC class is registered in 17 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Pomalidomide is registered in 17 of 19 countries.
Countries holding a registration under ATC L04AX06 (pomalidomide), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Pomalidomide · ATC L04AX06
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of pomalidomide costs, country by country.
Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Pomalidomide · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$255.48
The record
At a glance
Fimea (Finland)- Active substance
- Pomalidomide
- Manufacturer
- STADA Arzneimittel AG
- Country
- Finland (FI)
- ATC code
- L04AX06
- ATC class
- Pomalidomide
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa52225421 x 1EUR 398.23
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
277 interactions on record for pomalidomide.
Graded by severity as the source publishes them — 64 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pomalidomide · interactions on record
277 records
- 64 severe
- 213 moderate
Most severe, free to view
- ErythropoietinB03XA01severe
- Darbepoetin alfaB03XA02severe
- PeginesatideB03XA04severe
- C1-inhibitor, plasma derivedB06AC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L04AX06
Pomalidomide, as other registers publish it.
- CanadaAPO-POMALIDOMIDEAPOTEX INC
- CanadaAPO-POMALIDOMIDEAPOTEX INC
- CanadaAPO-POMALIDOMIDEAPOTEX INC
- CanadaAPO-POMALIDOMIDEAPOTEX INC
- PolandImnovidBristol-Myers Squibb Pharma EEIG
- FinlandImnovidBristol-Myers Squibb Pharma EEIG
- FinlandImnovidBristol-Myers Squibb Pharma EEIG
- NorwayImnovidBristol-Myers Squibb Pharma EEIG (1)
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/158b5502-ba20-4bdf-9f6e-dd2ebda17e40 GET /v1/drugs/158b5502-ba20-4bdf-9f6e-dd2ebda17e40?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "3",
"form": "kapseli, kova",
"route": "Suun kautta",
"ddd_unit": "mg",
"strength": "4 mg",
"atc_label": "pomalidomidi",
"ma_number": "42841",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL61906",
"authorised_at": "2025-02-21"
}See everything about pomalidomide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.